Biogen Inc. (BIIB)

288.81
4.00 1.40
NASDAQ : Health Technology
Prev Close 284.81
Open 287.59
Day Low/High 285.60 / 290.41
52 Wk Low/High 244.28 / 370.57
Volume 468.76K
Avg Volume 1.29M
Exchange NASDAQ
Shares Outstanding 211.56M
Market Cap 61.75B
EPS 11.90
P/E Ratio 24.00
Div & Yield N.A. (N.A)

Latest News

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

Biogen Reports Top-Line Results From Phase 2b Study Of Natalizumab In Acute Ischemic Stroke

Biogen Reports Top-Line Results From Phase 2b Study Of Natalizumab In Acute Ischemic Stroke

Biogen (Nasdaq: BIIB) announced today that in the Phase 2b dose-ranging ACTION 2 study in individuals with acute ischemic stroke (AIS), natalizumab did not demonstrate improvement in clinical outcomes compared to placebo.

Biogen To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Biogen To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Leerink Partners 7th Annual Global Healthcare Conference.

It's a Flash Sale!: Cramer's 'Mad Money' Recap (Wednesday 1/31/18)

It's a Flash Sale!: Cramer's 'Mad Money' Recap (Wednesday 1/31/18)

Jim Cramer explains how to rely on long-term themes to take advantage of this market's wild action.

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

The biotech sector has seen a big rally, but there are still opportunities.

Building in Biotech, Adding to Twitter

Building in Biotech, Adding to Twitter

The challenge of this market is to keep finding new buy entries as more and more stocks become extended.

Biogen, Celgene Jump on Earnings; Ford's Acquisitions Fail to Move Stock--ICYMI

Biogen, Celgene Jump on Earnings; Ford's Acquisitions Fail to Move Stock--ICYMI

Here's what you need to know now for Thursday, Jan. 25

Dow and S&P 500 Jump to New Records as Nasdaq Slips

Dow and S&P 500 Jump to New Records as Nasdaq Slips

The Dow soared 140 points on Thursday.

Stocks Lose Steam, Dow Holds Gains as Caterpillar Turns Lower

Stocks Lose Steam, Dow Holds Gains as Caterpillar Turns Lower

Stocks come off early highs after Caterpillar shares trade lower.

Davos, Caterpillar, Intel, Ford and Kroger - 5 Things You Must Know

Davos, Caterpillar, Intel, Ford and Kroger - 5 Things You Must Know

U.S. stock futures rise as the dollar plunges to a fresh three-year low. Caterpillar, Intel and 3M leading the earnings calendar.

Biogen Reports Record Revenues For Both The Full Year And Fourth Quarter Of 2017, $12.3 Billion And $3.3 Billion, Respectively

Biogen Reports Record Revenues For Both The Full Year And Fourth Quarter Of 2017, $12.3 Billion And $3.3 Billion, Respectively

Biogen Inc. (Nasdaq: BIIB) today reported full year and fourth quarter 2017 financial results, including: Full year total revenues of $12.

Tax Reform's Impact on the Economy

Tax Reform's Impact on the Economy

Consumer spending should be more than solid given wage increases.

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

With a boost from the NFL and its own IPO, Quanterix hopes to engage biopharma companies to use its platform to speed safety and efficacy results for neurology, oncology and inflammation pipelines.

Jim's Daily Rundown

In today's video, Jim discusses the government shutdown, an Eli Lilly downgrade, Schlumberger after Friday's earnings, and several other market-related topics.

Shutdown Enters Day 3, Sanofi Buys Bioverativ - 5 Things You Must Know

Shutdown Enters Day 3, Sanofi Buys Bioverativ - 5 Things You Must Know

U.S. stock futures suggest Wall Street will open lower on Monday, as investors watch for the impact of a federal government shutdown that has extended into its third day.

Sanofi Strikes $11.6 Billion Deal for Bioverativ

Sanofi Strikes $11.6 Billion Deal for Bioverativ

France's Sanofi could end its long search for a biotech deal after striking an $11.6 billion offer for Massachusetts-based Bioverativ, a maker of hemophilia treatments.

Biogen To Report Fourth Quarter And Year-End 2017 Financial Results On January 25, 2018- Updated Call Timing

Biogen To Report Fourth Quarter And Year-End 2017 Financial Results On January 25, 2018- Updated Call Timing

Biogen Inc. (NASDAQ:BIIB) today announced it will report fourth quarter and year-end 2017 financial results on Thursday, January 25, 2018, before the financial markets open.

Jim Cramer: Stocks Are on Fire For Good Reasons

Jim Cramer: Stocks Are on Fire For Good Reasons

Stocks put in broad gains supported by tax cuts, bonuses, a weaker dollar and more.

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.

Biogen Becomes #205 Most Shorted S&P 500 Component, Replacing Vulcan Materials

Biogen Becomes #205 Most Shorted S&P 500 Component, Replacing Vulcan Materials

The most recent short interest data has been released for the 12/15/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Stocks Close Higher as Wall Street Dissects New Tax Laws

Stocks Close Higher as Wall Street Dissects New Tax Laws

Major indexes held gains Thursday following passage of a $1.5 trillion U.S. tax bill that will slash corporate taxes.

Biogen To Report Fourth Quarter And Year-End 2017 Financial Results On January 25, 2018

Biogen To Report Fourth Quarter And Year-End 2017 Financial Results On January 25, 2018

Biogen Inc. (NASDAQ:BIIB) today announced it will report fourth quarter and year-end 2017 financial results on Thursday, January 25, 2018, before the financial markets open.

Biogen And Ionis Enter Into New Collaboration To Identify Novel Therapies For The Treatment Of Spinal Muscular Atrophy

Biogen And Ionis Enter Into New Collaboration To Identify Novel Therapies For The Treatment Of Spinal Muscular Atrophy

Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that they have entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of...

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech

These favorite names in the volatile sector offer the potential for high rewards.

Biogen To Present At The 36th Annual J.P. Morgan Healthcare Conference

Biogen To Present At The 36th Annual J.P. Morgan Healthcare Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the 36 th Annual J.

4 Signs the Bull Market in Stocks Remains Incredibly Strong

4 Signs the Bull Market in Stocks Remains Incredibly Strong

Growth is here to stay, and value is for more than just the old strongholds.

Biogen To Present At The Guggenheim 5th Annual Healthcare Conference

Biogen To Present At The Guggenheim 5th Annual Healthcare Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Guggenheim 5 th Annual Healthcare Conference.

TheStreet Quant Rating: B- (Buy)